» Articles » PMID: 33568052

ELAVL1 is Transcriptionally Activated by FOXC1 and Promotes Ferroptosis in Myocardial Ischemia/reperfusion Injury by Regulating Autophagy

Overview
Journal Mol Med
Publisher Biomed Central
Date 2021 Feb 11
PMID 33568052
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Myocardial ischemia is the most common form of cardiovascular disease and the leading cause of morbidity and mortality. Understanding the mechanisms is very crucial for the development of effective therapy. Therefore, this study aimed to investigate the functional roles and mechanisms by which ELAVL1 regulates myocardial ischemia and reperfusion (I/R) injury.

Methods: Mouse myocardial I/R model and cultured myocardial cells exposed to hypoxia/reperfusion (H/R) were used in this study. Features of ferroptosis were evidenced by LDH activity, GPx4 activity, cellular iron, ROS, LPO, and GSH levels. The expression levels of autophagy markers (Beclin-1, p62, LC3), ELAVL1 and FOXC1 were measured by qRT-PCR, immunostaining and western blot. RIP assay, biotin-pull down, ChIP and dual luciferase activity assay were employed to examine the interactions of ELAVL1/Beclin-1 mRNA and FOXC1/ELAVL1 promoter. CCK-8 assay was used to examine viability of cells. TTC staining was performed to assess the myocardial I/R injury.

Results: Myocardial I/R surgery induced ferroptosis and up-regulated ELAVL1 level. Knockdown of ELAVL1 decreased ferroptosis and ameliorated I/R injury. Si-ELAVL1 repressed autophagy and inhibition of autophagy by inhibitor suppressed ferroptosis and I/R injury in myocardial cells. Increase of autophagy could reverse the effects of ELAVL1 knockdown on ferroptosis and I/R injury. ELAVL1 directly bound with and stabilized Beclin-1 mRNA. Furthermore, FOXC1 bound to ELAVL1 promoter region and activated its transcription upon H/R exposure.

Conclusion: FOXC1 transcriptionally activated ELAVL1 may promote ferroptosis during myocardial I/R by modulating autophagy, leading to myocardial injury. Inhibition of ELAVL1-mediated autophagic ferroptosis would be a new viewpoint in the treatment of myocardial I/R injury.

Citing Articles

Different types of cell death and their interactions in myocardial ischemia-reperfusion injury.

Du B, Fu Q, Yang Q, Yang Y, Li R, Yang X Cell Death Discov. 2025; 11(1):87.

PMID: 40044643 PMC: 11883039. DOI: 10.1038/s41420-025-02372-5.


The RNA-binding protein ELAVL1 promotes Beclin1-mediated cellular autophagy and thus endometrial cancer development by affecting LncRNA-neat stability.

Luo Y, Zhong X, Sun X, Fan J Cancer Biol Ther. 2025; 26(1):2469927.

PMID: 40018990 PMC: 11875488. DOI: 10.1080/15384047.2025.2469927.


Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects.

Ru Q, Li Y, Zhang X, Chen L, Wu Y, Min J Bone Res. 2025; 13(1):27.

PMID: 40000618 PMC: 11861620. DOI: 10.1038/s41413-024-00398-6.


Knockdown gene by rAAV9 alleviates doxorubicin-induced cardiac toxicity by inhibiting GATA4 autophagic degradation.

Xu A, Shen Z, Wang S, Luan H, Xu Y, Kang Z Front Pharmacol. 2025; 15:1496380.

PMID: 39931517 PMC: 11808915. DOI: 10.3389/fphar.2024.1496380.


Curcumin attenuates myocardial ischemia‑reperfusion‑induced autophagy‑dependent ferroptosis via Sirt1/AKT/FoxO3a signaling.

Zhao S, Qiu Z, Xu Z, Tao E, Qiu R, Peng H Int J Mol Med. 2025; 55(3).

PMID: 39930816 PMC: 11781526. DOI: 10.3892/ijmm.2025.5492.


References
1.
de Bruin R, Rabelink T, van Zonneveld A, van der Veer E . Emerging roles for RNA-binding proteins as effectors and regulators of cardiovascular disease. Eur Heart J. 2017; 38(18):1380-1388. DOI: 10.1093/eurheartj/ehw567. View

2.
Zhou T, Chuang C, Zuo L . Molecular Characterization of Reactive Oxygen Species in Myocardial Ischemia-Reperfusion Injury. Biomed Res Int. 2015; 2015:864946. PMC: 4609796. DOI: 10.1155/2015/864946. View

3.
Zhao Y, Li J, Li D, Wang Z, Zhao J, Wu X . Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers. Semin Cancer Biol. 2019; 60:334-343. DOI: 10.1016/j.semcancer.2019.08.026. View